The Fortnightly May Also Be Found at Our Web Site Of: the FORTNIGHTLY a Review of Middle East Regional
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
SUU Alm.Del Bilag 444: Itamar Grotto
Sundheds- og Ældreudvalget 2017-18 SUU Alm.del Bilag 444 Offentligt MINISTRY OF HEALTH Medical Grade Cannabis - The Israeli Roadmap to Medicalization Prof. Itamar Grotto Associate Director General, Israeli Ministry of Health Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Medical use of Cannabis in ancient times • 5000 years ago in Egyptian tombs • 2700 years ago in India • 2000 years ago in China for the treatment of pain Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH International - Single Convention on Narcotic Drugs 1961 The Cannabis plant is subject to additional measures of control Israel - The Dangerous Drug Ordinance [New Version] - 1973 The Cannabis plant and its products are defined as narcotic substances They are not registered as medicinal products Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Government of Israel Resolutions Government Resolution 3609 (7.8.2011) • Establishes the obligation of the Ministry of Health to serve as “Government Agency” for Cannabis • The multi-ministerial Stirring Committee • The Israeli Medical Cannabis Agency (IMCA) is established Government Resolution 1050 (15.12.2013) • Improving efficiency of prescription, indication inspection, appointing of Physicians and accessibility to service. • Search for feasibility of export • Regulating research. Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Government Resolution 1587 (26.6.2016) - Cannabis for medical purpose and research The “Medicalization” of Cannabis Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Vision of The Israeli Medical Cannabis Agency (IMCA) To support the use of Cannabis for medical purposes exclusively, while preventing misuse and keeping public safety. -
Beyondborders 5Th Internationa
1 Καστελλόριζο - Εκεί όπου το ντοκιμαντέρ συναντά την Ιστορία και τον Πολιτισμό >>> Castellorizo - the Aegean Island where Documentaries meet History & Culture >>> 2 3 Υπό την αιγίδα / Under the auspices Γενική Γραμματεία Απόδημου Ελληνισμού Δήμος Μεγίστης General Secretariat for Greeks Abroad Municipality of Megisti ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ YΠΟΥΡΓΕΙΟ ΕΞΩΤΕΡΙΚΩΝ Γ.Γ Απόδημου Ελληνισμού ΔΗΜΟΣ ΜΕΓΙΣΤΗΣ Υπουργείο Πολιτισμού και Αθλητισμού ΔΙΕΘΝΕΣ ΦΕΣΤΙΒΑΛ ΝΤΟΚΙΜΑΝΤΕΡ Ministry of Culture and Sports 5ο ΠΕΡΑ ΑΠΟ ΤΑ Ένωση Σεναριογράφων Ελλάδος Union of Screenwriters of Greece ΣΥΝΟΡΑ Πρεσβεία των ΗΠΑ στην Αθήνα US Embassy in Athens BEYOND Πρεσβεία της Αυστραλίας στην Αθήνα th BORDERS Australian Embassy in Athens INTERNATIONAL DOCUMENTARY FESTIVAL Australian Embassy 5 Greece Πρεσβεία του Ισραήλ στην Αθήνα Israeli Embassy in Athens 23-30/8 2020 ΚΑΣΤΕΛΛΟΡΙΖΟ / CASTELLORIZO Πέρα από τα Σύνορα / Beyond Borders [email protected] www.beyondborders.gr Οργάνωση / Organization Ελληνικό Ίδρυμα Ιστορικών Μελετών (ΙΔΙΣΜΕ) / Hellenic History Foundation (ΙD.IS.ME.) Μπουμπουλίνας 1, 15351 Παλλήνη Αττικής / 1, Bouboulinas Str., Pallini, Attica 15351 T.: +30 210 6669 140, +30 210 6669 131 [email protected] www.idisme.gr Συνδιοργάνωση / Co-organization ΕΛΛΗΝΙΚΟ ΙΔΡΥΜΑ ΙΣΤΟΡΙΚΩΝ ΜΕΛΕΤΩΝ (ΙΔΙΣΜΕ) Les Écrans des Mondes Σύνδεσμος Αναβίωσης Μεγίστης (Σύδνεϋ) / Restoration Committee of Megisti (Sydney) HELLENIC HISTORY FOUNDATION (ΙDΙSΜΕ) Περιεχόμενα | Contents Συντελεστές & Συνεργάτες / Team & Associates _ Χαιρετισμοί | Addresses 7 _ Καστελλόριζο - Εκεί όπου το ντοκιμαντέρ -
Israeli Cannabis Company 'Together' Announced an Agreement with a Canadian Company to Sell 50 Tons of Cannabis Inflorescences Or 5 Tons of Cannabis Oil
Israeli cannabis company 'Together' announced an agreement with a Canadian company to sell 50 tons of cannabis inflorescences or 5 tons of cannabis oil The company estimates the potential annual revenue from the deal at hundreds of millions of shekels. "This agreement joins other existing sales agreements in Canada and German totaling 30 tons. These agreements ensure the creation of revenue and cash flow that are not dependent on export approval from the State of Israel, and which will derive from the sale of medical cannabis and its products from areas that we will set up in countries outside of Israel that have the relevant export agreements", said Globus Pharma founding partner Nissim Bracha Israel, Ashkelon, April 11 2018 – 'Together' (TASE: TGTR) announced that its activity company 'Globus Pharma', which specializes in the medical cannabis sector and operates as a subsidiary of 'Together', has signed a Memorandum of Understanding (MoU) to sell medical cannabis or oil to a Canadian company with a license to grow, produce and import medical cannabis to Canada. Under the terms of the agreement, the Canadian company will buy from Globus 50 tons of dried inflorescences of cannabis each year or five tons of medical cannabis oil (the equivalent amount to 50 tons of inflorescences) as part of the terms of the law in Canada and in Israel. In addition, the two companies will collaborate in the field of R&D and promoting technologies in the medical cannabis sector. As of the date of signing the agreement, the parties estimate that sales revenue will amount to between US$3.17 and US$4.7 per gram of inflorescence. -
Roots Sustainable Agricultural Technologies Ltd Arbn 619 754 540 Notice of Annual General Meeting
ROOTS SUSTAINABLE AGRICULTURAL TECHNOLOGIES LTD ARBN 619 754 540 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 2:30 pm (WST) DATE: Thursday, 16 September 2021 PLACE: Suite 2, Level 1 1 Altona Street WEST PERTH WA 6005 The business of the Meeting affects your shareholding and your vote is important. This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) and to section 182 of the Companies Law and the regulations promulgated thereunder, that the persons eligible to vote at the Meeting are those who are registered Shareholders at 5:00pm (WST) on 14 September 2021. BUSINESS OF THE MEETING AGENDA 1. FINANCIAL STATEMENT AND REPORTS Review and discussion of the audited annual financial report of the Company for the financial year ended 31 December 2020 together with the declaration of the directors, the director’s report and the auditor’s report. 2. RESOLUTION 1 – APPOINTMENT OF AUDITORS To consider and, if thought fit, to pass, with or without amendment, the following resolution: “RESOLVED, that BDO – Ziv Haft be, and hereby is, appointed as the independent auditors of the Company for the year 2021 and for an additional period until the next annual general meeting.” The affirmative vote of at least a majority of the voting power represented at the Meeting, in person or by proxy and voting thereon, is required to adopt this Resolution. -
Israel Takes the Next Steps Towards Legalizing Recreational Cannabis
Article Cannabis Law July 2020 Israel Takes the Next Steps Towards Legalizing Recreational Cannabis By Andrew J. Wilder and Jonathan Mahoney Israel is considered one of the global leaders in medical cannabis research and innovation. In 1964, Professor Raphael Mechoulam of the Hebrew University of Jerusalem was the first person to isolate and identify THC, the psychoactive chemical component in cannabis that causes a high. While limited use of cannabis for medicinal purposes has been permitted in Israel since the early 1990s, it took 53 years from Professor Mechoulam’s breakthrough before the Public Security Ministry partially decriminalized cannabis in 2017, setting fines and treatment for initial offenders instead of criminal procedures. Earlier this year, after much bureaucratic delay, the export of medical cannabis was finally approved and is estimated to generate hundreds of millions of dollars in revenue annually. Now, three years since its decriminalization, Israel is on the verge of legalizing cannabis for recreational use. On June 9th, 2020, just one week after the State of Israel police minister declared that enforcement of the existing laws related to cannabis possession and use would be relaxed, two of Israel’s largest political parties issued a joint statement, agreeing to move forward with cannabis law reform. In the joint statement provided by Likud Prime Minister Benjamin Netanyahu and Blue and White’s Defense Minister Benny Gantz, they advised that reform to existing legislation was required with the aim to “resolve the issue of decriminalization and legalization” of cannabis in Israel. In addition to legalizing recreational cannabis, the proposed reforms will also make it easier for patients to gain access to treatment and for producers to become licensed to grow and sell medical cannabis. -
(Emblem) OFFICIAL GOVERNMENT GAZETTE of the HELLENIC
(Emblem) OFFICIAL GOVERNMENT GAZETTE OF THE HELLENIC REPUBLIC 9 March 2021 1ST ISSUE No. 36 LAW No. 4782 Modernization, simplification and reform of the public procurement regulatory framework, specifications on the procurement for defense and security and other provisions for development, infrastructure and health. THE PRESIDENT OF THE HELLENIC REPUBLIC We issue the following law adopted by the Parliament: TABLE OF CONTENTS PART A’ ISSUES OF PUBLIC PROCUREMENT, SERVICES AND WORKS CONTRACTS CHAPTER A’ DEFINITIONS Article 1 Definitions - Amendment of the title and par. 1, 2, 3 and 4 of article 2 of Law 4412/2016 CHAPTER B’ AWARD PROCEDURE Article 2 Settlement of issues of appeal in a negotiated procedure without prior publication - Replacement of article 32A of Law 4412/2016 Article 3 Electronic auctions - Amendment of the title and addition of par. 11 to article 34 of Law 4412/2016 Article 4 Obligation to use - Operation of the National System for Online Public Contracts (ESIDIS) - Amendment of the title and replacement of article 36 of Law 4412/2016 Article 5 Security policy of ESIDIS - Amendment of par. 3, 4 and 5 of article 37 of Law 4412/2016 Article 6 Central Electronic Public Procurement Registry (KIMDIS) - Amendment of the title and par. 1, 2, 3, 4, 5, 6 and 10 of article 38 of Law 4412/2016 Article 7 National Central Purchasing Bodies and public procurement planning - Amendment of the title and replacement of article 41 of Law 4412/2016 Article 8 Procedures for the award of contracts with contracting authorities from different Member States - Amendment of par. -
FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer
FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer: MPX International Corporation (“MPXI” or the “Issuer”). Trading Symbol: MPXI This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited condensed interim financial statements are to be filed under the Securities Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website. Currency Unless otherwise stated, all dollar amounts are expressed in Canadian dollars. General Instructions (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer. (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries. (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions. -
Bol-Pharma-Prospectus.Pdf
A copy of this preliminary prospectus has been filed with the securities regulatory authorities in each of the provinces and territories of Canada but has not yet become final for the purpose of the sale of securities. Information contained in this preliminary prospectus may not be complete and may have to be amended. The securities may not be sold until a receipt for the prospectus is obtained from the securities regulatory authorities. No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘‘U.S. Securities Act’’), or the securities laws of any state of the United States and may not be offered or sold, directly or indirectly, in the United States or in any other jurisdiction where the offer or sale of such securities is not permitted, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws, or securities laws of any other relevant jurisdiction. This prospectus does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction where the offer, sale or solicitation of an offer to buy any of these securities is not permitted. See ‘‘Plan of Distribution’’. -
Review of Contemporary Knowledge of the Treatment Effects Of
Review of Contemporary Knowledge of the Treatment Effects of Cannabis and Related Products, and Its Outlook Tomáš Zábranský 1, 4), Lumír Hanuš 1, 2, 4), Richard Rokyta 1, 3, 4) 1) International Cannabis and Cannabinoids Institute, Prague 2) Hebrew University in Jerusalem, Israel 3) Department of Normal, Pathological and Clinical Physiology, 3rd Faculty of Medicine, Charles University in Prague 4) Společnost pro léčbu konopím a kanabinoidy a jejich výzkum, z.s. [Czech Society for Medical Treatment with Cannabis and Cannabinoids and Their Research] CONTENTS CONTENTS .............................................................................................................................................................. 1 ABSTRACT............................................................................................................................................................... 3 KEY WORDS ............................................................................................................................................................ 3 RECOMMENDED CITATION: .................................................................................................................................... 4 INTRODUCTION ...................................................................................................................................................... 4 METHODS .............................................................................................................................................................. -
Patterns of Use of Medical Cannabis Among Israeli
Vol. 49 No. 2 February 2015 Journal of Pain and Symptom Management 223 Original Article Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience Barliz Waissengrin, MD, Damien Urban, MD, Yasmin Leshem, MD, Meital Garty, BA, and Ido Wolf, MD Institute of Oncology (B.W., M.G., I.W.), Tel Aviv Sourasky Medical Center, Tel Aviv; Institute of Oncology (D.U., Y.L.), Chaim Sheba Medical Center, Ramat Gan; and Sackler Faculty of Medicine (I.W.), Tel Aviv University, Tel Aviv, Israel Abstract Context. The use of the cannabis plant (Cannabis sativa L.) for the palliative treatment of cancer patients has been legalized in multiple jurisdictions including Israel. Yet, not much is currently known regarding the efficacy and patterns of use of cannabis in this setting. Objectives. To analyze the indications for the administration of cannabis among adult Israeli cancer patients and evaluate its efficacy. Methods. Efficacy and patterns of use of cannabis were evaluated using physician-completed application forms, medical files, and a detailed questionnaire in adult cancer patients treated at a single institution. Results. Of approximately 17,000 cancer patients seen, 279 (<1.7%) received a permit for cannabis from an authorized institutional oncologist. The median age of cannabis users was 60 years (range 19e93 years), 160 (57%) were female, and 234 (84%) had metastatic disease. Of 151 (54%) patients alive at six months, 70 (46%) renewed their cannabis permit. Renewal was more common among younger patients and those with metastatic disease. Of 113 patients alive and using cannabis at one month, 69 (61%) responded to the detailed questionnaire. -
Annual Information Form
CRONOS GROUP INC. ANNUAL INFORMATION FORM For the year ended December 31, 2018 DATED: March 25, 2019 TABLE OF CONTENTS GENERAL MATTERS ............................................................................................................................................... 3 FORWARD LOOKING INFORMATION ............................................................................................................... 3 CORPORATE STRUCTURE .................................................................................................................................... 6 GENERAL DEVELOPMENT OF THE BUSINESS ............................................................................................... 7 DESCRIPTION OF THE BUSINESS ..................................................................................................................... 13 ALTRIA STRATEGIC INVESTMENT ................................................................................................................. 39 RISK FACTORS ....................................................................................................................................................... 43 DIVIDENDS AND DISTRIBUTIONS ..................................................................................................................... 76 CAPITAL STRUCTURE .......................................................................................................................................... 76 MARKET FOR SECURITIES ................................................................................................................................ -
Cooperation Council Between the Government of the Hellenic Republic and the Government of the Republic of Bulgaria Alexandroupolis, 26.02.2020
JOINT DECLARATION OF THE 4TH HIGH LEVEL – COOPERATION COUNCIL BETWEEN THE GOVERNMENT OF THE HELLENIC REPUBLIC AND THE GOVERNMENT OF THE REPUBLIC OF BULGARIA ALEXANDROUPOLIS, 26.02.2020 The Prime Minister of the Republic of Bulgaria Mr. Boyko Borissov and the Prime Minister of the Hellenic Republic Mr. Kyriakos Mitsotakis at the close of the Fourth meeting of the Bulgarian – Hellenic High Cooperation Council, held in Alexandroupolis on February 26th, 2020 and attended from the Bulgarian side by Mrs. Ekaterina Zaharieva, Deputy Prime Minister and Minister of Foreign Affairs, Mr. Krassimir Karakatchanov, Deputy Prime Minister and Minister of Defence, , Mr. Mladen Marinov, Minister of Interior, Mrs. Petya Avramova, Minister of Regional Development and Public Works, Mr. Boil Banov, Minister of Culture, Mr. Rossen Zhelyazkov, Minister of Transport, Information Technology and Communications, Mr. Emil Karanikolov, Minister of Economy, Mrs. Temenuzhka Petkova, Minister of Energy, Mrs. Nikolina Angelkova, Minister of Tourism, and from the Hellenic side by Mr. Spyridon-Adonis Georgiadis, Minister for Development and Investments, Mr. Nikolaos-Georgios Dendias, Minister for Foreign Affairs, Mr. Michail Chryssochoidis, Minister of Citizen Protection, Mr. Nikolaos Panagiotopoulos, Minister of National Defense, Mrs. Styliani Mendoni, Minister for Culture and Sports, Mr. Konstantinos A. Karamanlis, Minister of Infrastructures and Transport, Mr. Theoharis Theoharis, Minister of Tourism, Mr. Georgios Koumoutsakos, Alternate Minister for Migration and Asylum,